

05-02-2003

REC/PCT/PTO 04 APR 2003

10/240213 AD



102436888

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

RECORDATION FORM COVER SHEET  
PATENTS ONLY

Attorney Docket No.: 056291-5115

To the Commissioner for Patents  
Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

1. Peter David Davis  
2. Graeme Dougherty

4-4-03

Additional names of conveying party(ies) attached?  
 Yes  No

2. Name and address of receiving party(ies):

Name: AstraZeneca AB

Internal Address:

Street Address: S-151 85 Sodertalje, Sweden

City:  
State: Zip:

Additional name(s) & address(es) attached?  
 Yes  No

3. Nature of conveyance:

Assignment  Merger  
 Security Agreement  Change of Name  
 Other

Execution Dates: 1. September 18, 2002  
2. September 26, 2002

4. New Application number(s) or patent number(s): 10/240,213

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s)  
Additional numbers attached:  Yes  No

B. Patent No.(s)

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Donald J. Bird

Internal Address: Morgan, Lewis & Bockius LLP  
Customer No. 09629

Street Address: 1111 Pennsylvania Avenue, N.W.  
City: Washington State: D.C. Zip: 20004

6. Total number of applications and patents involved:

7. Total fee (37 C.F.R. §3.41): \$40.00  
 Enclosed  
 Authorized to be charged to Deposit Account 50-0310

8. Deposit Account No. 50-0310  
 (Attach duplicate page if paying by deposit account)

9. Statement and Signature  
 To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Donald J. Bird Reg. No. 25,323  
Name of Person Signing

Signature

April 4, 2003  
Date

Total number of pages including cover sheet, attachments and documents: 2

04/09/2003 BFREY1 00000076 500310 10240213  
03 FC:8021 40.00 CH

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR (S),

**PETER DAVID DAVIS AND GRAEME DOUGHERTY**

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE, AstraZeneca AB, a company created and existing under the laws of Sweden, having its Head Office at S-151 85 Sodertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled: COMBINATION THERAPIES WITH VASCULAR DAMAGING ACTIVITY

And which is found in

- (a) \_\_\_ U.S. patent application executed on even date herewith;
- (b) \_\_\_ U.S. patent application executed on \_\_\_\_\_;
- (c) \_\_\_ U.S. application serial no. Filed on \_\_\_\_\_;
- (d) X International application no. **PCT/GB01/01317 FILED ON 27<sup>TH</sup> MARCH 2001**

And any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent any reissue or reexamination thereof;

ASSIGNOR (S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR (S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

Signed this Day of 18<sup>th</sup> September, 2002

**PETER DAVID DAVIS CHIEF EXECUTIVE OFFICER  
ANGIOGENE PHARMACEUTICALS LTD**

WITNESS: [Signature]  
K M DAVIS

WITNESS: [Signature]  
DJ. CHARLTON

DATE: 18 September 2002

DATE: 18 September 2002

Signed this Day of 26<sup>th</sup> September, 2002

[Signature]  
**GRAEME DOUGHERTY**

WITNESS: [Signature]  
SHONA T DOUGHERTY

WITNESS: [Signature]  
SIMON A. MCCALLUM

DATE: 26<sup>th</sup> September 2002

DATE: 26<sup>th</sup> September 2002